Zimmer Biomet Holdings, Inc.

ZBH

NYSEHealthcareMedical - Devices

在 GoAI 中打开

前收盘价

US$100.98

+US$2.01 · +2.03%

8月21日 16:00 ET

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

61/ 100

GoAI评分

Buy

Favorable setup — positive multi-factor alignment

估值

Deep Value

动量

Neutral

情绪

Mixed

风险韧性

Moderate Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

行业: Medical - Devices
部门: Healthcare
总部: US
首席执行官: Ivan Tornos
上市以来: 2001年7月25日
雇员: 17,000

市场位置

日内区间

当前US$100.98，

US$99.06US$101.15

52周区间

当前US$100.98，

US$79.12US$108.29

开盘价: US$99.06
前收盘价: US$98.97
成交量: 88.16万; 0.37× 平均值
平均成交量: 241.24万; 日均成交量
市值: 195.36亿 USD
贝塔: 0.46; 市场参考 1
50天平均值: US$92.6426; 高于平均水平+9.00%
200天平均值: US$90.8906; 高于平均水平+11.10%

财务数据

财务快照

估值与收益率

企业价值: 247.31亿 USD
市盈率（TTM）: 24.45×
市净率（TTM）: 1.54×
市销率（TTM）: 2.3×
EV/EBITDA: 11.15×
盈利收益率: 3.96%
自由现金流收益率: 8.27%
股息率: 0.95%

盈利能力和效率

毛利率: 69.87%
营业利润率: 15.73%
净利润率: 9.48%
净资产收益率: 5.55%
资产收益率: 3.05%
投入资本回报率: 5.48%

财务健康

负债权益比: 0.59×
流动比率: 1.98×

分析师评级

第三方分析师预期可能变化，并非 GoAI 建议。

评级分布

42项评级

强力买入00%

买入1740%

持有2252%

卖出37%

强力卖出00%

ZBH 消息

zacks.com2026年8月20日

Is Zimmer Biomet Stock Worth Retaining in Your Portfolio Now?

ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.

阅读源码

defenseworld.net2026年8月11日

Zimmer Biomet Q2 Earnings Call Highlights

Zimmer Biomet (NYSE: ZBH) reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology…

阅读源码

zacks.com2026年8月10日

Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

阅读源码

marketbeat.com2026年8月9日

Zimmer Biomet Q2 Earnings Call Highlights

Zimmer Biomet NYSE: ZBH reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped…

阅读源码